• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Can HFpEF and HFrEF Coexist?射血分数保留的心力衰竭和射血分数降低的心力衰竭会共存吗？
Circulation. 2020 Mar 3;141(9):709-711. doi: 10.1161/CIRCULATIONAHA.119.045171. Epub 2020 Mar 2.
2
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.射血分数对沙库巴曲缬沙坦（LCZ696）治疗射血分数降低的心力衰竭的疗效及预后的影响：ARNI与ACEI对心力衰竭全球死亡率和发病率影响的前瞻性比较（PARADIGM-HF）试验
Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
3
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.血管紧张素受体脑啡肽酶抑制剂用于射血分数降低的心力衰竭患者：来自台湾的真实世界经验
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):152-157. doi: 10.1177/1074248419872958. Epub 2019 Sep 12.
4
Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.从雷米普利转换为沙库巴曲缬沙坦可有益地改变射血分数降低的心力衰竭患者的心室复极心电图指标。
Acta Cardiol. 2020 Feb;75(1):20-25. doi: 10.1080/00015385.2018.1535818. Epub 2018 Dec 4.
5
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.PARAGON-HF 试验中射血分数保留的心力衰竭患者的基线特征。
Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.
6
Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry.左心室射血分数对急性心力衰竭后肾素-血管紧张素系统阻滞剂疗效的影响：来自 KCHF 注册研究。
PLoS One. 2020 Sep 14;15(9):e0239100. doi: 10.1371/journal.pone.0239100. eCollection 2020.
7
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.血管紧张素受体-脑啡肽酶抑制剂与标准治疗相比用于射血分数降低的心力衰竭患者的估计 5 年治疗需要人数，以预防心血管死亡或心力衰竭住院：来自 PARADIGM-HF 试验的数据分析。
JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957.
8
Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.心力衰竭住院后使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂进行出院治疗与更好的预后相关，而与左心室射血分数无关。
Intern Med J. 2019 Dec;49(12):1505-1513. doi: 10.1111/imj.14289.
9
The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.PARADIGM-HF 试验在真实世界的门诊环境中的合格人群及其 2005 年至 2016 年期间的心血管风险。
J Cardiovasc Med (Hagerstown). 2020 Jan;21(1):6-12. doi: 10.2459/JCM.0000000000000889.
10
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.与 PARADIGM-HF 试验相比，CHAMP-HF 注册研究中纳入患者的特征和治疗。
J Am Heart Assoc. 2018 Jun 12;7(12):e009237. doi: 10.1161/JAHA.118.009237.

引用本文的文献

1
A Need to Preserve Ejection Fraction during Heart Failure.心力衰竭时需要保持射血分数。
Int J Mol Sci. 2024 Aug 12;25(16):8780. doi: 10.3390/ijms25168780.
2
Development and validation of algorithms to predict left ventricular ejection fraction class from healthcare claims data.从医疗保健索赔数据中开发和验证预测左心室射血分数等级的算法。
ESC Heart Fail. 2024 Jun;11(3):1688-1697. doi: 10.1002/ehf2.14725. Epub 2024 Mar 4.
3
Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy.大tau 聚集破坏微管酪氨酸化，导致心肌舒张功能障碍：从发现到治疗。
Eur Heart J. 2023 May 1;44(17):1560-1570. doi: 10.1093/eurheartj/ehad205.
4
Dirty Jobs: Macrophages at the Heart of Cardiovascular Disease.脏活：巨噬细胞是心血管疾病的核心因素
Biomedicines. 2022 Jul 2;10(7):1579. doi: 10.3390/biomedicines10071579.
5
Myocardial Fatigue: a Mechano-energetic Concept in Heart Failure.心肌疲劳：心力衰竭的机械能量学概念。
Curr Cardiol Rep. 2022 Jun;24(6):711-730. doi: 10.1007/s11886-022-01689-2. Epub 2022 Mar 30.
6
Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.沙库巴曲缬沙坦在伴有心脏植入式电子装置心力衰竭患者管理中的应用。
Am J Cardiovasc Drugs. 2021 Jul;21(4):383-393. doi: 10.1007/s40256-020-00448-4. Epub 2020 Oct 28.
7
Metabolic inflammation in heart failure with preserved ejection fraction.射血分数保留的心力衰竭中的代谢炎症。
Cardiovasc Res. 2021 Jan 21;117(2):423-434. doi: 10.1093/cvr/cvaa217.
8
Reappraisal on pharmacological and mechanical treatments of heart failure.心力衰竭的药理学和机械治疗再评价。
Cardiovasc Diabetol. 2020 May 6;19(1):55. doi: 10.1186/s12933-020-01024-5.

本文引用的文献

1
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.沙库巴曲缬沙坦与缬沙坦对射血分数保留心力衰竭女性与男性患者的影响：PARAGON-HF 研究的见解。
Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.
2
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
3
Nitrosative stress drives heart failure with preserved ejection fraction.硝化应激导致射血分数保留型心力衰竭。
Nature. 2019 Apr;568(7752):351-356. doi: 10.1038/s41586-019-1100-z. Epub 2019 Apr 10.
4
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

Can HFpEF and HFrEF Coexist?

作者信息

Schiattarella Gabriele G, Tong Dan, Hill Joseph A

机构信息

Departments of Internal Medicine (Cardiology) (G.G.S., D.T., J.A.H.), University of Texas Southwestern Medical Center, Dallas.

Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas.

出版信息

Circulation. 2020 Mar 3;141(9):709-711. doi: 10.1161/CIRCULATIONAHA.119.045171. Epub 2020 Mar 2.

DOI:10.1161/CIRCULATIONAHA.119.045171
PMID:32119583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7080323/
Abstract
摘要